NCT02923947 is a Phase 1 clinical trial of Osimertinib; AZD9291 in Solid Tumours, sponsored by AstraZeneca.

Who is sponsoring NCT02923947?

NCT02923947 is sponsored by AstraZeneca.

What drugs are being tested in NCT02923947?

Interventions in NCT02923947: Osimertinib; AZD9291.

What condition does NCT02923947 study?

NCT02923947 studies Solid Tumours.

Is NCT02923947 still recruiting?

NCT02923947 is currently completed. Last updated 27 November 2023.

Last reviewed 2023-11-27 · How we verify

NCT02923947

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

Completed Phase 1 Last updated 27 November 2023

What this trial tests

Phase 1 trial testing Osimertinib; AZD9291 in Solid Tumours in 16 participants. Completed in 28 October 2022.

Timeline

4 May 2017

Primary endpoint
20 September 2018

28 October 2022

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	4 May 2017
Primary completion	20 September 2018
Estimated completion	28 October 2022
Sites	11 locations across France, Spain, South Korea

Drugs / interventions tested

Osimertinib; AZD9291 — full drug profile →

Conditions studied

Solid Tumours — all drugs for Solid Tumours →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, any sex, with Solid Tumours. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the effect of severe renal impairment on the levels of AZD9291 in the blood in patients with advanced solid tumours compared to patients with normal renal function

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
Vishwanathan K, Sanchez-Simon I, Keam B, Penel N, et al · · 2020 · cited 9× · PMID 32567817 · DOI 10.1002/prp2.613

Verify or expand the search:

Other recruiting trials for Solid Tumours

Currently open trials in the same condition.

NCT07391670 — A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durval · Phase 1 · recruiting
NCT07446855 — Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homo · Phase 1, PHASE2 · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07165067 — A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02923947 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 27 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02923947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing